#pennystock

ARTL Surges 40%! The Story of Breaking Into the Glaucoma Market Without Spending a Dime

They say biotech stocks are all about 'expectations,' but this time, a real catalyst dropped. I'll pick out just the facts and explain in the easiest way possible why people are suddenly going wild over ARTL and whether there's an actual chance this drug makes it.